title: The Budget Impact of Hepatitis C Treatment in Ireland 2001-2012.
abstract: Chronic Hepatitis C (HCV) is estimated to infect 20,000 to 50,000 people in Ireland. National estimates of the number of patients who have been treated for HCV, their demographics and the cost associated with that treatment have not been published. Prescriptions for the treatment of HCV from 2000-2012 were established by interrogating the records of the High-Tech Drug Scheme and the pharmacy records of the Genitourinary Medicine and Infectious Diseases department of St. James Hospital. 2320 patients were initiated on treatment for HCV. Over €27 million was spent on HCV treatment. €25.5 million was spent on anti-viral therapy and €2 million was spent on haematological growth factor support for the management of adverse effects. The budget impact of HCV treatment has been significant in Ireland. New agents for HCV will have a greater budget impact but should require less spend on adverse event management.
authors.forename: J
authors.initials: J
authors.lastname: Kieran
authors.forename: K
authors.initials: K
authors.lastname: Bennett
authors.forename: M
authors.initials: M
authors.lastname: Coghlan
authors.forename: C
authors.initials: C
authors.lastname: Bergin
authors.forename: M
authors.initials: M
authors.lastname: Barry
mesh_terms: D000998:Antiviral Agents / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use*; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000191:economics* / Q000453:epidemiology; D006801:Humans; D007494:Ireland / Q000453:epidemiology
chemical_list: D000998:Antiviral Agents